Advertisement
BSX vs NTRA
Which Stock Would AI Choose? Boston Scientific (BSX) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Boston Scientific (BSX) boasts a market capitalization of about $90.6 billion, dwarfing Natera (NTRA)'s $29.4 billion, reflecting its established position in medical devices.
- BSX shares have fallen approximately 11% in recent weeks amid sector headwinds and slowing growth in electrophysiology, while NTRA displays upward momentum with bullish technical crossovers.
- NTRA, focused on genetic diagnostics, shows higher volatility (beta 1.68) compared to BSX's steadier profile (beta 0.78), appealing to growth-oriented traders.
- Analyst targets point to potential upside: $96.66 average for BSX and $257.95 for NTRA, amid BSX's upcoming earnings and NTRA's product adoption.
- Tickeron's AI tools highlight NTRA's positive trend consistency over BSX's recent downtrend in relative performance analysis.
Introduction
This BSX vs. NTRA stock comparison examines two healthcare innovators amid shifting market dynamics. Boston Scientific excels in medical devices, while Natera leads in genetic diagnostics. Traders eyeing sector rotation or relative strength, and investors assessing growth versus stability, will find value here. Recent market activity has highlighted contrasts in momentum and sentiment, influenced by earnings anticipation, technical signals, and broader healthcare trends. This analysis draws on verifiable data to illuminate their positioning for informed decision-making in today's volatile environment.
BSX Overview and Recent Performance
Boston Scientific Corporation (BSX) develops and markets medical devices across cardiovascular, MedSurg, and neuromodulation segments, including stents, pacemakers, and endoscopy tools. In recent market activity, BSX shares have declined about 11% over the past 30 days and significantly year-to-date, pressured by slowing electrophysiology growth and macroeconomic factors. Sentiment reflects analyst price target adjustments downward, though a consensus "Buy" rating persists ahead of Q1 earnings. Key influences include competitive dynamics and anticipation of revenue growth to $5.19 billion, underscoring resilience in its diversified portfolio despite short-term volatility.
NTRA Overview and Recent Performance
Natera, Inc. (NTRA) specializes in molecular diagnostics, offering tests like Signatera for cancer monitoring (minimal residual disease, or MRD) and Panorama for non-invasive prenatal screening. Recent weeks have seen NTRA exhibit upward trends, with its 10-day moving average crossing above the 50-day average and positive MACD signals, supporting momentum amid year-to-date gains. Growing adoption of its cell-free DNA platforms and analyst initiations like "Outperform" have bolstered sentiment, though high beta reflects sensitivity to biotech swings. Performance drivers include partnerships and expanding clinical utility in oncology and organ transplant monitoring.
Trending AI Robots
Tickeron’s Trending AI Robots page curates over 25 top-performing bots from a library of 351 AI trading agents that analyze thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies—such as swing trading, trend-following, momentum, and multi-agent systems—with timeframes from 5 minutes to 60 days. Featured bots boast impressive stats, including annualized returns of 34% to 168%, win rates of 55% to 88%, profit factors up to 11.7, and profit-to-drawdown ratios exceeding 20 in some cases. Selected for suitability in current volatile conditions like semiconductor surges and sector rotations, they offer copy-trading options via virtual or brokerage agents. Explore these high-conviction signals to enhance your trading edge.
Head-to-Head Comparison
BSX and NTRA both thrive in healthcare but diverge in models: BSX delivers steady device revenues with profitability (P/E 31.44), while NTRA pursues high-growth diagnostics, remaining unprofitable with elevated risk. Growth drivers contrast BSX's cardiovascular innovations against NTRA's oncology and prenatal catalysts. Recent momentum favors NTRA's bullish patterns over BSX's declines; risk profiles show NTRA's higher beta amplifying biotech exposure versus BSX's defensive stability. Market sentiment tilts toward NTRA's technical strength amid BSX's earnings wait.
Tickeron AI Verdict
Tickeron’s AI currently leans toward NTRA based on stronger trend consistency, upward moving average crossovers, and positive momentum indicators, contrasting BSX's bearish signals like Aroon downtrends and recent declines. While BSX offers scale and earnings catalysts, NTRA's relative positioning suggests higher near-term probability of outperformance in the current market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BSX is a Hold and NTRA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BSX’s FA Score shows that 0 FA rating(s) are green whileNTRA’s FA Score has 0 green FA rating(s).
- BSX’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BSX’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 4 bullish TA indicator(s).
- BSX’s TA Score: 4 bullish, 4 bearish.
- NTRA’s TA Score: 4 bullish, 5 bearish.
Price Growth
BSX (@Medical/Nursing Services) experienced а -5.25% price change this week, while NTRA (@Medical Specialties) price change was -9.19% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.24%. For the same industry, the average monthly price growth was -2.86%, and the average quarterly price growth was -3.42%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +6.04%. For the same industry, the average monthly price growth was +3.13%, and the average quarterly price growth was -6.19%.
Reported Earning Dates
BSX is expected to report earnings on Jul 29, 2026.
NTRA is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (+0.24% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+6.04% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| BSX | NTRA | BSX / NTRA | |
| Capitalization | 78.9B | 28B | 282% |
| EBITDA | 5.49B | -227.7M | -2,412% |
| Gain YTD | -44.352 | -14.741 | 301% |
| P/E Ratio | 22.20 | N/A | - |
| Revenue | 20.6B | 2.5B | 824% |
| Total Cash | 1.45B | 1.09B | 134% |
| Total Debt | 11B | 240M | 4,583% |
BSX | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 69 | 16 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 66 Overvalued | 56 Fair valued | |
PROFIT vs RISK RATING 1..100 | 84 | 52 | |
SMR RATING 1..100 | 56 | 94 | |
PRICE GROWTH RATING 1..100 | 65 | 50 | |
P/E GROWTH RATING 1..100 | 98 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (56) in the Biotechnology industry is in the same range as BSX (66) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
NTRA's Profit vs Risk Rating (52) in the Biotechnology industry is in the same range as BSX (84) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
BSX's SMR Rating (56) in the Medical Specialties industry is somewhat better than the same rating for NTRA (94) in the Biotechnology industry. This means that BSX’s stock grew somewhat faster than NTRA’s over the last 12 months.
NTRA's Price Growth Rating (50) in the Biotechnology industry is in the same range as BSX (65) in the Medical Specialties industry. This means that NTRA’s stock grew similarly to BSX’s over the last 12 months.
BSX's P/E Growth Rating (98) in the Medical Specialties industry is in the same range as NTRA (100) in the Biotechnology industry. This means that BSX’s stock grew similarly to NTRA’s over the last 12 months.
| BSX | NTRA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | N/A |
| Stochastic ODDS (%) | 1 day ago 56% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 49% | 1 day ago 82% |
| MACD ODDS (%) | 1 day ago 58% | 1 day ago 72% |
| TrendWeek ODDS (%) | 1 day ago 52% | 1 day ago 77% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 80% |
| Advances ODDS (%) | 8 days ago 58% | 3 days ago 80% |
| Declines ODDS (%) | 4 days ago 53% | 16 days ago 78% |
| BollingerBands ODDS (%) | 1 day ago 61% | 1 day ago 81% |
| Aroon ODDS (%) | 1 day ago 58% | 1 day ago 84% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHE | 36.41 | 0.37 | +1.03% |
| Schwab Emerging Markets Equity ETF™ | |||
| IDYN | 31.05 | 0.31 | +1.00% |
| iShares Intl Eq Fac Rotation Act ETF | |||
| NKX | 12.56 | 0.05 | +0.40% |
| Nuveen California AMT-Free Quality Municipal Income Fund | |||
| MJ | 26.23 | 0.01 | +0.04% |
| Amplify Alternative Harvest ETF | |||
| IVRS | 33.44 | N/A | N/A |
| iShares Future Metaverse Tec And Com ETF | |||